Table 1:

Demographic characteristics at study entry among PWH in the NA-ACCORD and under observation for mental health outcomes between 2008–2018 (N=122,896).

	Overall		Depression				Anxiety				Bipolar Disorder				Schizophrenia
	N=122,896		No Depression n=75,343		Depression n=47,553		No Anxiety n=88,677		Anxiety n=34,219		No Bipolar Disorder n=111,189		Bipolar Disorder n=11,716		No Schizophrenia n=117,874		Schizophrenia n=5,022
Characteristics	n	%	n	%	n	%	n	%	n	%	n	%	n	%	N	%	n	%
Age
Median (IQR)	46 (37–54)		45 (35–53)		47 (39–55)		46 (36–54)		47 (39–54)		46 (37–54)		46 (38–53)		46 (37–54)		51 (44–57)
Sex
Male	104062	85%	63524	84%	40538	85%	74216	84%	29846	87%	94408	85%	9654	82%	99687	85%	4375	87%
Female	18832	15%	11819	16%	7013	15%	14458	16%	4374	13%	16770	15%	2062	18%	18184	15%	648	13%
Race
Non-Hispanic White	44816	36%	25796	34%	19019	40%	29022	33%	15794	46%	39626	36%	5190	44%	43516	37%	1300	26%
Non-Hispanic Black	52196	42%	32902	44%	19295	41%	40677	46%	11519	34%	47384	43%	4812	41%	49163	42%	3033	60%
Hispanic	17651	14%	10938	15%	6713	14%	12557	14%	5094	15%	16382	15%	1269	11%	17100	15%	551	11%
Non-Hispanic Asian	2219	2%	1517	2%	703	1%	1714	2%	505	1%	2125	2%	94	1%	2186	2%	33	1%
Other/Unknown	6014	5%	4191	6%	1823	4%	4706	5%	1308	4%	5663	5%	351	3%	5908	5%	106	2%
HIV acquisition risk
IDU	21115	17%	10656	14%	10459	22%	12265	14%	8850	26%	16487	15%	4628	40%	18452	16%	2663	53%
MSM	42869	35%	28477	38%	14392	30%	32157	36%	10712	31%	39954	36%	2915	25%	42379	36%	490	10%
Heterosexual contact	24662	20%	17061	23%	7601	16%	20609	23%	4053	12%	22916	21%	1746	15%	23987	20%	675	13%
Other/Unknown	34250	28%	19149	25%	15101	32%	23645	27%	10605	31%	31823	29%	2427	21%	33055	28%	1195	24%
Smoking
Never	26585	22%	15963	21%	10621	22%	18691	21%	7892	23%	24978	22%	1607	14%	25991	22%	594	12%
Ever	61191	50%	32229	43%	28963	61%	39501	45%	21690	63%	52673	47%	8518	73%	57253	49%	3938	78%
Not assessed	35120	29%	27151	36%	7969	17%	30484	34%	4636	14%	33529	30%	1591	14%	34629	29%	491	10%
Hepatitis C infection	25009	20%	13459	18%	11551	24%	16323	18%	8686	25%	21006	19%	4003	34%	22814	19%	2195	44%
Hepatitis B infection	7004	6%	4196	6%	2808^*	6%	5084	6%	1920^*	6%	6268	6%	736^*	6%	6681	6%	323^*	6%
Treated hypertension	36543	30%	19099	25%	17445	37%	23625	27%	12918	38%	32221	29%	4322	37%	34030	29%	2513	50%
Diabetes	12136	10%	6577	9%	5559	12%	8447	10%	3689	11%	10803	10%	1333	11%	11209	10%	927	18%
CKD stage 2 (eGFR <60)
No	103064	84%	61511	82%	41553	87%	72926	82%	30138	88%	92597	83%	10467	89%	98721	84%	4343	86%
Yes	7978	6%	4669	6%	3309	7%	5792	7%	2186	6%	7295	7%	683	6%	7547	6%	431	9%
Not assessed	11854	10%	9163	12%	2691	6%	9958	11%	1896	6%	11288	10%	566	5%	11605	10%	249	5%
Hypercholesterolemia	26243	21%	14206	19%	12035	25%	17154	19%	9089	27%	23286	21%	2957	25%	24921	21%	1322	26%
Statin Use	20674	17%	11003	15%	9671	20%	13625	15%	7049	21%	18631	17%	2043^*	17%	19608	17%	1066^*	21%
CD4 count (cells/mm³)
Median (IQR)	431 (251–634)		428 (247–630)		435 (258–643)		421 (240–626)		454 (279–657)		430 (250–629)		439 (265–642)		423 (234–631)		412 (237–612)
<200	19986	16%	12521	17%	7465	16%	15293	17%	4693	14%	18317	16%	1669	14%	19212	16%	774	15%
>=200	85238	70%	51917	69%	33321	70%	60584	69%	24654	72%	77174	70%	8064	69%	82142	70%	3096	61%
Missing	17571	14%	10905	14%	6727	14%	12799	14%	4873	14%	15689	14%	1983	17%	16519	14%	1153	23%
HIV RNA (copies/mL)
<200	43075	35%	26436	35%	16638	35%	31138	35%	11937	35%	39150	35%	3925	34%	41604	35%	1471	29%
>=200	51433	42%	32139	43%	19294	41%	37676	42%	13757	40%	46465	42%	4968	42%	49448	42%	1985	40%
Missing	28388	23%	16768	22%	11621	24%	19862	22%	8526	25%	25565	23%	2823	24%	26821	23%	1567	31%
Year of ART initiation
1996–2004	33820	28%	17283	23%	16537	35%	22135	25%	11685	35%	29805	26%	4015	34%	31748	27%	2072	41%
2005–2009	26728	22%	16041	21%	10687	22%	19484	22%	7244	21%	24120	22%	2608	22%	25761	22%	967	19%
2010–2018	48644	40%	32385	43%	16259	34%	36322	41%	12322	36%	44853	40%	3791	32%	47515	40%	1129	22%
Not initiate ART	13690	11%	9622	13%	4068	9%	10726	12%	2964	9%	12391	11%	1299	11%	12835	11%	855	17%
HIV treatment regimen at ART initiation
NNRTI	14770	12%	10107	13%	4663	10%	10841	12%	3929	12%	13655	12%	1115	10%	14495	12%	275	5%
PI	6609	5%	3913	5%	2696	6%	4689	5%	1920	6%	6023	5%	586	5%	6408	5%	201	4%
Integrase Inhibitor	42922	35%	25933	35%	16989	36%	30968	35%	11954	35%	39322	36%	3600	31%	41553	35%	1369	27%
Other/Unknown	44343	36%	25402	34%	18941	40%	31021	35%	13322	39%	39266	35%	5077	43%	42029	36%	2314	46%
Never on HAART	13690	11%	9622	13%	4068	9%	10726	12%	2964	9%	12391	11%	1299	11%	12835	11%	855	17%

P-values calculated using chi-squared tests for all categorical or binary variables and t-tests for all continuous variables.

All p-values are <0.001, unless specified with (*).

Due to large numbers of participants statistical significance was common, however clinical significance was considered as a difference in 5% between comparison groups and these differences are bolded.

Age, sex, race/ethnicity, and HIV transmission acquisition group are time-fixed variables, measured at enrollment into the NA-ACCORD.

IDU: injection drug use, MSM: Men who have sex with men, NNRTI: non-nucleoside reverse transcriptase inhibitor, PI: Protease inhibitor.